This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Metastatic Melanoma
and you are
over 18
years old
This is a medium phase trial determining
the safety and dosage of the new treatment, as well as its efficacy.
Show me locations

The purpose

The purpose of this study is to determine whether the intravenous and/or GM-CT-01 administration can correct Tumor Infiltrating Lymphocytes (TIL) anergy and induce a more efficient and long-lasting anti-tumoral immune response following peptide vaccination.

Provided treatments

  • Biological: Tumor specific peptides: MAGE-3.A1 and / or NA17.A2
  • Biological: Galectin-3 inhibitor: GM-CT-01 systemic injections
  • Biological: Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01723813. The sponsor of the trial is Cliniques universitaires Saint-Luc- Université Catholique de Louvain and it is looking for 6 volunteers for the current phase.
Official trial title:
Phase I/II Study of Peptide Vaccination Associated With GM-CT-01, a Galactomannan Oligomer That Inhibits Galectin-3, in Patients With Advanced Metastatic Melanoma